Found: 300
Select item for more details and to access through your institution.
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.
- Published in:
- 2008
- By:
- Publication type:
- journal article
An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer.
- Published in:
- Current Oncology Reports, 2024, v. 26, n. 8, p. 855, doi. 10.1007/s11912-024-01525-6
- By:
- Publication type:
- Article
The evolving landscape of tissue‐agnostic therapies in precision oncology.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 433, doi. 10.3322/caac.21844
- By:
- Publication type:
- Article
Images in Immunotherapy and Precision Oncology: Advanced Basal Cell Carcinoma.
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 3, p. 201, doi. 10.36401/JIPO-23-47
- By:
- Publication type:
- Article
How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center Experience.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241273053
- By:
- Publication type:
- Article
Therapy of T Cell Lymphomas with Pentostatin.
- Published in:
- Annals of the New York Academy of Sciences, 2001, v. 941, n. 1, p. 200, doi. 10.1111/j.1749-6632.2001.tb03724.x
- By:
- Publication type:
- Article
Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.
- Published in:
- Integrative Cancer Therapies, 2018, v. 17, n. 4, p. 1012, doi. 10.1177/1534735418801524
- By:
- Publication type:
- Article
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2017, v. 35, n. 5, p. 616, doi. 10.1007/s10637-017-0442-3
- By:
- Publication type:
- Article
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 4, p. 911, doi. 10.1007/s10637-015-0251-5
- By:
- Publication type:
- Article
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 621, doi. 10.1007/s10637-015-0226-6
- By:
- Publication type:
- Article
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 700, doi. 10.1007/s10637-015-0238-2
- By:
- Publication type:
- Article
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 177, doi. 10.1007/s10637-014-0173-7
- By:
- Publication type:
- Article
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 1, p. 215, doi. 10.1007/s10637-014-0176-4
- By:
- Publication type:
- Article
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1181, doi. 10.1007/s10637-014-0121-6
- By:
- Publication type:
- Article
Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 717, doi. 10.1007/s10637-014-0104-7
- By:
- Publication type:
- Article
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 465, doi. 10.1007/s10637-013-0051-8
- By:
- Publication type:
- Article
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 2, p. 279, doi. 10.1007/s10637-013-9966-3
- By:
- Publication type:
- Article
Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 1, p. 154, doi. 10.1007/s10637-013-9964-5
- By:
- Publication type:
- Article
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1192, doi. 10.1007/s10637-013-0003-3
- By:
- Publication type:
- Article
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 967, doi. 10.1007/s10637-013-9929-8
- By:
- Publication type:
- Article
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 918, doi. 10.1007/s10637-012-9898-3
- By:
- Publication type:
- Article
A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 1, p. 327, doi. 10.1007/s10637-010-9536-x
- By:
- Publication type:
- Article
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
- Published in:
- Investigational New Drugs, 2010, v. 28, n. 5, p. 634, doi. 10.1007/s10637-009-9273-1
- By:
- Publication type:
- Article
Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 7, p. 408, doi. 10.1002/ajh.21423
- By:
- Publication type:
- Article
Carcinoma of unknown primary: Molecular tumor board‐based therapy.
- Published in:
- CA: A Cancer Journal for Clinicians, 2022, v. 72, n. 6, p. 510, doi. 10.3322/caac.21748
- By:
- Publication type:
- Article
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
- Published in:
- 1991
- By:
- Publication type:
- journal article
Rearrangement in the Breakpoint Cluster Region and the Clinical Philadelphia-Negative Chronic Myelogenous Leukemia.
- Published in:
- Annals of Internal Medicine, 1986, v. 105, n. 5, p. 673, doi. 10.7326/0003-4819-105-5-673
- By:
- Publication type:
- Article
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 6, p. 642, doi. 10.1111/ejh.13702
- By:
- Publication type:
- Article
Phase II Evaluation of Gemcitabine Monotherapy for Cutaneous T-Cell Lymphoma.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 1, p. 51
- By:
- Publication type:
- Article
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD anderson cancer center experience.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases.
- Published in:
- Clinical Colorectal Cancer, 2010, v. 9, n. 5, p. 311, doi. 10.3816/CCC.2010.n.045
- By:
- Publication type:
- Article
Chemotherapy Resistance and Retreatment: A Dogma Revisited.
- Published in:
- Clinical Colorectal Cancer, 2010, v. 9, n. 2, p. E1, doi. 10.3816/CCC.2010.n.026
- By:
- Publication type:
- Article
How to detect skin signs of malignancy.
- Published in:
- Patient Care (Print), 2002, v. 36, n. 5, p. 21
- By:
- Publication type:
- Article
Letter to the editor.
- Published in:
- Clinical Anatomy, 2006, v. 19, n. 7, p. 682, doi. 10.1002/ca.20356
- By:
- Publication type:
- Article
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
- Published in:
- Experimental Hematology & Oncology, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40164-020-00159-1
- By:
- Publication type:
- Article
Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.01312
- By:
- Publication type:
- Article
Unilateral Proptosis.
- Published in:
- 2013
- By:
- Publication type:
- Case Study
Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers.
- Published in:
- Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00979-8
- By:
- Publication type:
- Article
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
- Published in:
- Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00969-w
- By:
- Publication type:
- Article
Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-00753-2
- By:
- Publication type:
- Article
MHC-I genotype and tumor mutational burden predict response to immunotherapy.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-00743-4
- By:
- Publication type:
- Article
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-0714-y
- By:
- Publication type:
- Article
Alpha Interferon Dose-Dependent Suppression of Secondary Clones in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia.
- Published in:
- Acta Haematologica, 1990, v. 83, n. 3, p. 149, doi. 10.1159/000205193
- By:
- Publication type:
- Article
Intensive Combination Chemotherapy and Interferons in the Management of Chronic Myelogenous Leukemia.
- Published in:
- Acta Haematologica, 1987, v. 78, n. S1, p. 70, doi. 10.1159/000205906
- By:
- Publication type:
- Article
Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1663, doi. 10.3390/ijms18081663
- By:
- Publication type:
- Article
Chronic myelogenous leukemia and sweet syndrome.
- Published in:
- American Journal of Hematology, 1989, v. 32, n. 2, p. 134, doi. 10.1002/ajh.2830320211
- By:
- Publication type:
- Article
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia.
- Published in:
- American Journal of Hematology, 1988, v. 29, n. 1, p. 1, doi. 10.1002/ajh.2830290102
- By:
- Publication type:
- Article
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00487-5
- By:
- Publication type:
- Article
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00449-x
- By:
- Publication type:
- Article